Patents Assigned to IPSEN PHARMA
  • Melanocortin Receptor Ligands
    Publication number: 20180105557
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: December 4, 2017
    Publication date: April 19, 2018
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, Jacques-Pierre MOREAU
  • Thiazole derivatives for treating dyskinesias caused by a chemical treatment
    Patent number: 9918967
    Abstract: The invention relates to the use of derivatives of thiazoles having general formula (I) for the preparation of a medicament for the treatment or prevention of dyskinesias caused by a chemical treatment. The invention also relates to a combination of thiazole derivatives having general formula (I) and at least one compound selected from among neuroleptics or products that act on the dopaminergic system for the treatment or prevention of dyskinesias caused by a chemical treatment.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: March 20, 2018
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Pierre-Etienne Chabrier de Lassauniere, Michel Auguet, Brigitte Spinnewyn
  • Melanocortin receptor ligands
    Patent number: 9850280
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 26, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Jacques-Pierre Moreau
  • Growth Hormone Releasing Peptides
    Publication number: 20170362275
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2?? (I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: August 29, 2017
    Publication date: December 21, 2017
    Applicant: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin DONG
  • Use of melanocortins to treat insulin sensitivity
    Patent number: 9827286
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: November 28, 2017
    Assignees: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. Halem, Michael DeWitt Culler, Andrew A. Butler
  • METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE
    Publication number: 20170304403
    Abstract: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 26, 2017
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, John E. TAYLOR, Rakesh DATTA, Michael DeWitt CULLER
  • Somatostatin analogs and dimers thereof
    Patent number: 9777039
    Abstract: The present invention relates to novel somatostatin analogs, dimers thereof, and methods of using the same to treat various diseases. Naturally occurring somatostatins (SSTs), which are also known as somatotropin release-inhibiting factors (SRIFs), have diverse biological effects in many cells and organs 10 throughout the body. They are produced by normal endocrine, gastrointestinal, immune and neuronal cells, as well as by certain tumors (Patel, Y. C, Frontiers in Neuroendocrinology, 20(3): 157-198 (1999); Froidevaux, et al., Biopolymers, 66(3): 161-83 (2002)).
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: October 3, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Eric Ferrandis
  • Melanocortin receptor ligands modified with hydantoin
    Patent number: 9758549
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: September 12, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock
  • Melanocortin Receptor Ligands
    Publication number: 20170240595
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, Jacques-Pierre MOREAU
  • MACROCYCLIC LRRK2 KINASE INHIBITORS
    Publication number: 20170240565
    Abstract: The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Application
    Filed: September 17, 2015
    Publication date: August 24, 2017
    Applicants: Oncodesign S.A., Ipsen Pharma S.A.S.
    Inventors: Jan Hoflack, Petra Blom, Olivier Lavergne, Sylvie Gomez
  • Somatostatin-dopamine chimeric analogs
    Patent number: 9731027
    Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: August 15, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen, Sun Hyuk Kim
  • Sustained release formulations comprising very low molecular weight polymers
    Patent number: 9724397
    Abstract: The present invention relates to a parenteral, sustained and controlled release, semisolid formulation comprising an end-capped oligomer and at least one active substance without any supplementary viscosity reducing agent or excipient.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: August 8, 2017
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Roland Cherif-Cheikh, Anne-Paula De Sousa Delgado, Frédéric Lacombe, Laurence Lachamp, Didier Bourissou
  • Imidazolidine-2,4-dione derivatives
    Patent number: 9676752
    Abstract: Imidazolidine-2,4-dione derivatives of formula (I): The compounds have anti-proliferative activity and are useful for treating pathological states and diseases linked to an abnormal cell proliferation such as cancer.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: June 13, 2017
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Serge Auvin, Christophe Lanco, Qi Chao, Kaichun Gu
  • Somatostatin-dopamine chimeric analogs
    Patent number: 9603942
    Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: March 28, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen
  • Composition and Methods for Stimulating Gastrointestinal Motility
    Publication number: 20170037104
    Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.
    Type: Application
    Filed: October 25, 2016
    Publication date: February 9, 2017
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Rakesh DATTA, Zheng Xin DONG
  • Use of Melanocortins to Treat Insulin Sensitivity
    Publication number: 20160354429
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 8, 2016
    Applicants: Ipsen Pharma S.A.S., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Heather A. HALEM, Michael DeWitt CULLER, Andrew A. BUTLER
  • Clay compositions
    Patent number: 9511023
    Abstract: The present invention relates to liquid or semi-solid pharmaceutical compositions, more specifically to aqueous pharmaceutical suspension or semi-solid paste containing natural mineral clays as active ingredients. These compositions are particularly useful for the treatment of acute and chronic diarrhea.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: December 6, 2016
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Béatrice Hacher, Didier Kubiak, Jeremiah Harnett, Nathalie Mondoly
  • Composition and methods for stimulating gastrointestinal motility
    Patent number: 9499599
    Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: November 22, 2016
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Rakesh Datta, Zheng Xin Dong
  • Growth Hormone Releasing Peptides
    Publication number: 20160311855
    Abstract: Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: R1-A1-A2-A3-A4-A5-R2?? (I) wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 is Apc, Dab, Dap, Lys, Orn, or deleted; R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and R2 is OH or NH2; and pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 7, 2016
    Publication date: October 27, 2016
    Applicant: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin DONG
  • Melanocortin receptor ligands
    Patent number: 9458195
    Abstract: The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: October 4, 2016
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Jacques-Pierre Moreau